ClinicalTrials.gg
CompletedNCT05504343Updated Oct 3, 2023

Assessing The Visual Performance Of Hanita Lenses "Intensity SL" Intraocular Lens

An interventional study of "Intensity SL" Intraocular Lens in Cataract, sponsored by Hanita Lenses. Completed at 1 site in India. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Hanita Lenses · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2021, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cataract by Hanita Lenses — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Hanita Lenses.

Started
2021
the only one that year
No phase
8 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Cataract by Hanita Lenses, this one is the only one that started in 2021, is one of 8 with no phase, and was the 6th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 10 studies in Cataract by Hanita Lenses are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cataract by Hanita Lenses, or all of them as a file.
02

Study summary

The Hanita Lenses Intensity SL IOL is intended for implantation in the capsular bag in the posterior chamber in order to replace the crystalline lens of the eye to attain visual correction of aphakia in adult patients in whom a cataractous lens has been removed, who desire improved uncorrected vision, useful near, intermediate and far visual functions, and reduced spectacle dependence.

Read the detailed description

Different multifocal intraocular lens (MIOL) designs have been used for more than 25 years1. Unlike conventional mono focal intraocular lenses (IOLs), which bend light to a single focus point on the retina, MIOLs are designed to help patients to see at varying distances using different points of focus2. MIOLs used in clinical practice were either refractive initially, or later diffractive in their optical design. Refractive MIOLs incorporate a lens optic with different optical powers in different parts of the lens, while diffractive MIOLs use diffractive steps on the lens to distribute light rays into two or more principal foci. Irrespective of the design type, however, all MIOLs involve some form of optical compromise and a process of neuroadaptation for the patient3.

Intensity SL intraocular lenses (IOLs) represent the latest in premium lens technology. Intensity SL lenses provide clear vision at all distances - from near to far - thus offering the best chance of true spectacle independence.

Despite the promising results obtained with the latest generation of MIOLs, many surgeons remain reluctant to implant these lenses. Visual symptoms such as glare and haloes, reduced contrast sensitivity and night vision problems are all known complications of multifocal implants and have served to hamper wider acceptance of these IOLs4.

Hanita Lenses new Intensity SL IOL has been designed to have very high efficiency of light leading to a high MTF, wide focal ranges of far, intermediate and near vision and minimal loss of light energy. The main purpose of this study is to evaluate visual acuity and contrast sensitivity patients receiving the new Intensity SL IOL.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age over 45 years and under 75 years.

      • Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;
      • Calculated IOL power is within range 15-30 Diopter (approximate range of axial lengths: 21-25.5mm)
      • Normal corneas with corneal astigmatism below following value:

        1. 1 D if with-the-rule (steep axis is vertical, between 60-120⁰)
        2. 0.4 D if against-the-rule (steep axis is horizontal, 0-30⁰ or 150-180⁰)
        3. 0.7 D if oblique (not one of the cases above)
      • Post-operative best corrected visual acuity expected to be 0.3 logMAR or better.
      • Patient motivated for Intensity SL IOL after screening by surgeon.
      • Fundus visualization is possible.
      • Absence of retinal or optic nerve diseases
      • Signed

Exclusion criteria

Exclusion Criteria:

  • Any of the following condition will render a subject ineligible for inclusion in the analysis:

    • Previous ocular/corneal surgery that may affect refraction accuracy or visual acuity.
    • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
    • History or evidence of any ocular disease that may affect visual acuity (i.e. uncontrolled glaucoma, ocular injury, corneal pathologies, retinal pathologies in general and macular pathologies in particular, diabetic retinopathy, uveitis, aniridia or iris atrophy, vitreous pathologies (patients with vitreous separation or floaters can be included).
    • Rubella cataract.
    • Amblyopia
    • Significantly dry eye
    • Any other ocular condition that may predispose a subject to future complications or contraindicate implantation of the Intensity SL lens.
    • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
    • Patients with pupil diameter greater than 4mm in photopic conditions.
    • Pregnant, lactating, or planning to become pregnant during the course of the trial.
    • Allergy or intolerance to required study medications (including antibiotic).
    • Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days.
    • Traumatic cataract.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Single Arm

    This study is a prospective, single arm single center, open label study.

    Device: "Intensity SL" Intraocular Lens

Interventions

  • Device"Intensity SL" Intraocular Lens

    Cataract surgery and intraocular lens implantation

06

What researchers measure

Primary outcomes

  1. Binocular Visual Acuity

    Binocular visual acuity for far, intermediate and near distance are measured using an ETDRS chart or PV numbers for distance and PV Numbers Near Vision Card (Precision Vision) for near (40cm) and intermediate distances (80cm). Visual acuity is measured in photopic conditions.

    Time frame: 3 months

Secondary outcomes

  1. Defocus Curve

    Defocus Curve is measured using ETDRS chart or PV numbers. A loss of ≥ 3 lines (≥ 15 letters) on an ETDRS chart is considered moderate visual loss. A loss of ≥ 6 lines (≥ 30 letters) is considered severe. Patient's pupil diameter will be evaluated using a phoropter to create defocus in 0.5D increments, starting from 1D to -4D relative to emmetropia so that the patient will be corrected for far vision.

    Time frame: 3 months

  2. Contrast Sensitivity

    Contrast Sensitivity is measured using a sine wave gratings chart (FACT) at mesopic and photopic conditions. Luminance for photopic conditions will be 85cd/m² and 5cd/m² for mesopic conditions. The working interval for photopic conditions is 75-95cd/m² and for mesopic conditions is 5-15cd/m². Luminance for photopic and mesopic conditions will be monitored using Illuminance meter and documented.

    Time frame: 3 months

  3. Patients Satisfaction

    Patient Satisfaction is measured using the modified VF-14 questionnaire for quality of life, in addition to satisfaction questionnaire. VF-14 stands for Visual Function questionnaire version 14. Function: High score = better Visual Phenomenon: High score = better Satisfaction: Very happy / Happy / Less Happy / Unhappy

    Time frame: 3 months

Other outcomes

  1. Toxicity after IOL implantation

    Occurrence of adverse events associated with treating patients diagnosed with binocular cataract with Intensity SL IOL implantation.

    Time frame: 3 months

07

Study locations

1 site
  • Agrawal
    Chennai, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 12 months.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 17, 2022
StartActual
Dec 27, 2021
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05504343
Lead sponsor
Hanita Lenses
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Dec 27, 2021
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Last update
Oct 3, 2023

Study contacts

Dr. Suvodip Shaw
study director · Dr. Agarwal's Eye Hospital Limited
Dr Ashvin Agarwal
principal investigator · Dr. Agarwal's Eye Hospital Limited
Priyanka S.
study chair · Dr. Agarwal's Eye Hospital Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion